Follow-up imaging guidelines for patients with stage iii unresectable nsclc: recommendations based on the pacific trial

HIGHLIGHTS

• who: Jenny J. Ko and colleagues from the Department of Medical Oncology, BC Cancer-Abbotsford, Marshall Road, Abbotsford, BC V S , Canada CancerCare Manitoba Research Institute, CancerCare Manitoba, University of Manitoba, McDermot have published the article: Follow-Up Imaging Guidelines for Patients with Stage III Unresectable NSCLC: Recommendations Based on the PACIFIC Trial, in the Journal: (JOURNAL)
• what: As highlighted previously, the trial showed that regardless of whether durvalumab was received, patients with stage III, unresectable NSCLC who received curative-intent therapy had the highest risk of relapse in the first year after CRT .
 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.